Cambridge Consultants
| | More

8th March 2004

Encouraging Signs in UK Technology Markets

This week sees the second successful flotation on the UK hi-tech market in as many weeks. Ark Therapeutics Group plc is the first biotech company to list on the London Stock Exchange for a number of years. Cambridge Consultants Ltd's (CCL) IPO team wrote the independent Expert's Report which formed part of Ark's listing prospectus addressing the merits of Ark's products, aspects of its business plan and associated risks.

Ark is an emerging healthcare company with a product already in hospitals for the treatment of leg ulcers (Kerraboot®), with three further lead products including novel gene-based therapies, in late stage clinical development. The company has a complex portfolio of both product and device, an unusual mix for today's healthcare companies, and focuses on specialist medicines in areas where there are high unmet clinical needs. CCL's team therefore needed to cover medical devices for woundcare through to the application of gene therapy in oncology.

Ark's listing follows hot on the heels of Cambridge Silicon Radio (CSR plc) which floated last week, a spin-off of CCL.

"Glimmers of hope are finally appearing in the European technology market following Ark's announcement," said Dr Monika Green, leader of CCL's healthcare consulting arm. "We have seen a rise in confidence across the technology sector, and now we are seeing it in Biotech which has been particularly subdued over the last couple of years," she continued.

Notes for editors:

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology critical issues for clients worldwide.  For over 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies.  With a team of over 300 engineers, designers, scientists and consultants, in offices in Cambridge (UK) and Boston (USA), Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, transport, energy, cleantech and wireless communications. 

Created by three Cambridge graduates in 1960, the company has grown into a leading technology business, renowned worldwide for its ability to solve technical problems and provide innovative, practical solutions to commercial issues.  In 2009, the company was awarded the prestigious Queen’s Award for Enterprise in International Trade, and in 2011 was awarded a second Queen's Award, this time for Innovation. For more information visit: www.CambridgeConsultants.com

Cambridge Consultants is part of Altran, global leader in innovation and high-tech engineering consulting. Altran supports companies in the creation and development of their new products and services. For thirty years, the Group has been providing services to key players in the fields of Aerospace, Automotive, Energy, Railways, Finance, Healthcare, and Telecoms. Present at every stage of project development from new-technology strategic planning through to manufacturing, Altran is able to capitalise on its expertise in four key domains: Product Lifecycle Management, Mechanical Engineering, Systems Engineering & Embedded Systems and IT Systems. With a global network of 17,000 collaborators (including 15,000 consultants) and 500 major clients throughout the world, the Group reported sales of €1,420m in 2011. More info: www.altran.com

This release is not for distribution in the United States, Canada, Japan or Australia. The information contained herein does not constitute an offer of Ark securities for sale in the United States, Canada, Japan or Australia. Ark securities may not be offered or sold in the United States absent registration under the US Securities Act or an exemption therefrom. Ark has not and does not intend to register any of its securities under US securities law. Accordingly, Ark securities may not be offered or sold in the United States unless they are registered or exempt from registration under applicable law or in transactions that are exempt from registration. Ark securities will not be offered or sold to the public in the United States.


For further information:

Cambridge Consultants

Patrick Pordage
Marketing Communications Director
Tel: +44 1223 420024
Patrick.Pordage@CambridgeConsultants.com

;